TABLE 2.
Rates of antimicrobial resistance interpreted according to EUCAST 2021 breakpoints
| Antimicrobial categories | Antimicrobial agent | % Resistant isolates N = 100 |
|---|---|---|
| Penicillins | Ampicillin/amoxicillin | 48 |
| Piperacillin | 41 | |
| Ticarcillin | 45 | |
| Antipseudomonal penicillins + beta-lactamase inhibitors | Piperacillin-tazobactam | 5 |
| Penicillins + beta-lactamase inhibitors | Amoxicillin/clavulanic acid | 26 |
| Non-broad spectrum cephalosporins: 1st & 2nd generation | Cefuroxime | 3 |
| Broad-spectrum cephalosporins: 3rd & 4th generation | Cefixime | 1 |
| Cefotaxime | 0 | |
| Ceftazidime | 0 | |
| Cefepime | 0 | |
| Broad-spectrum cephalosporins+beta-lactamase inhibitor | Ceftolozane-tazobactam | 0 |
| Ceftazidime-avibactam | 0 | |
| Carbapenems | Imipenem | 0 |
| Ertapenem | 0 | |
| Meropenem | 0 | |
| Monobactams | Aztreonam | 1 |
| Fluroquinolones | Norfloxacin | 28 |
| Ciprofloxacin | 18 | |
| Levofloxacin | 17 | |
| Aminoglycosides | Gentamicin | 17 |
| Tobramycin | 16 | |
| Amikacin | 4 | |
| Glycylcyclines | Tigecycline | 0 |
| Nitrofuran derivatives | Nitrofurantoin | 2 |
| Phosphonic acids | Fosfomycin | 4 |
| Folate pathway inhibitors | Trimethoprim | 35 |
| Trimethoprim-sulfamethoxazole | 24 | |
| Polymyxins | Colistin | 0 |
| MDR (resistant to ≥ one agent in ≥ 3 antimicrobial categories) | 30 |